AstraZeneca PLC (NASDAQ:AZN - Free Report) - Equities researchers at Zacks Research reduced their Q2 2025 earnings per share estimates for shares of AstraZeneca in a note issued to investors on Wednesday, April 17th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.14 per share for the quarter, down from their previous forecast of $1.15. The consensus estimate for AstraZeneca's current full-year earnings is $4.02 per share. Zacks Research also issued estimates for AstraZeneca's Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.63 EPS, Q1 2026 earnings at $1.20 EPS and FY2026 earnings at $5.09 EPS.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). The firm had revenue of $12.02 billion for the quarter, compared to analysts' expectations of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.69 EPS.
Several other analysts also recently weighed in on the company. Morgan Stanley assumed coverage on AstraZeneca in a research note on Tuesday, January 23rd. They set an "overweight" rating on the stock. Jefferies Financial Group downgraded AstraZeneca from a "buy" rating to a "hold" rating in a research note on Wednesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of "Moderate Buy" and an average target price of $80.00.
Read Our Latest Stock Analysis on AZN
AstraZeneca Stock Performance
AstraZeneca stock traded down $0.17 during trading hours on Thursday, hitting $68.36. 4,005,867 shares of the stock traded hands, compared to its average volume of 6,177,931. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64. The firm's 50 day moving average price is $66.02 and its 200-day moving average price is $65.85. The stock has a market capitalization of $211.94 billion, a price-to-earnings ratio of 35.69, a P/E/G ratio of 1.25 and a beta of 0.50. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $76.56.
AstraZeneca Increases Dividend
The business also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were paid a $0.965 dividend. This is an increase from AstraZeneca's previous Semi-Annual dividend of $0.47. The ex-dividend date was Thursday, February 22nd. This represents a dividend yield of 2.3%. AstraZeneca's dividend payout ratio is presently 100.52%.
Institutional Trading of AstraZeneca
A number of hedge funds have recently modified their holdings of AZN. Fairfield Bush & CO. purchased a new stake in shares of AstraZeneca in the first quarter worth about $28,000. Panagora Asset Management Inc. raised its holdings in AstraZeneca by 55.1% in the 1st quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company's stock worth $793,000 after purchasing an additional 4,249 shares during the period. BlackRock Inc. raised its holdings in AstraZeneca by 22.0% in the 1st quarter. BlackRock Inc. now owns 7,466,492 shares of the company's stock worth $495,328,000 after purchasing an additional 1,343,939 shares during the period. Great West Life Assurance Co. Can raised its holdings in AstraZeneca by 102.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 525 shares of the company's stock worth $36,000 after purchasing an additional 266 shares during the period. Finally, Moors & Cabot Inc. raised its holdings in AstraZeneca by 2.8% in the 1st quarter. Moors & Cabot Inc. now owns 10,841 shares of the company's stock worth $719,000 after purchasing an additional 292 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
About AstraZeneca
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
